Keeping an Eye on Mineralys Therapeutics Inc (MLYS) After Insider Trading Activity

Jaxson Clark

Mineralys Therapeutics Inc’s recently made public that its Director Slingsby Brian Taylor unloaded Company’s shares for reported $43.35 million on Nov 20 ’25. In the deal valued at $43.35 per share,1,000,000 shares were sold. As a result of this transaction, Slingsby Brian Taylor now holds 7,903,838 shares worth roughly $336.7 million.

Then, Catalys Pacific Fund, LP bought 1,000,000 shares, generating $42,120,000 in total proceeds.

Before that, Levy Adam Scott sold 119,524 shares. Mineralys Therapeutics Inc shares valued at $5,363,716 were divested by the CFO and Secretary at a price of $44.88 per share. As a result of the transaction, Levy Adam Scott now holds 19,396 shares, worth roughly $0.83 million.

Jefferies initiated its Mineralys Therapeutics Inc [MLYS] rating to a Hold in a research note published on June 11, 2025; the price target was $15. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early July with a ‘”a Buy”‘ rating. Goldman began covering MLYS with “Buy” recommendation on April 02, 2024. Wells Fargo started covering the stock on March 07, 2023. It rated MLYS as “an Overweight”.

Price Performance Review of MLYS

On Monday, Mineralys Therapeutics Inc [NASDAQ:MLYS] saw its stock jump 1.74% to $42.6. Over the last five days, the stock has lost -3.75%. Mineralys Therapeutics Inc shares have risen nearly 238.10% since the year began. Nevertheless, the stocks have risen 246.06% over the past one year. While a 52-week high of $47.65 was reached on 11/12/25, a 52-week low of $8.24 was recorded on 02/25/25.

Levels Of Support And Resistance For MLYS Stock

The 24-hour chart illustrates a support level at 41.78, which if violated will result in even more drops to 40.96. On the upside, there is a resistance level at 43.66. A further resistance level may holdings at 44.72.

How much short interest is there in Mineralys Therapeutics Inc?

A steep rise in short interest was recorded in Mineralys Therapeutics Inc stocks on 2025-10-31, dropping by 38250.0 shares to a total of 6.84 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 6.88 million shares. There was a decline of -0.56%, which implies that there is a negative sentiment for the stock.

The most recent change occurred on March 07, 2023 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $45 price target.

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.